The antibody recognizes both wtEGFR and EGFRvIII. Survival in EGFR expressing GBM patients was significantly less than that in non-expressing patients (median survival: 12.5 versus 17.5 months, p = 0.013). The gene discussed is EGFR; the disease is glioblastoma.